Keros Therapeutics Announces Update on Patient Enrollment in Phase 2 TROPOS Trial Page 1

LEXINGTON, Mass., Sept. 3, 2024 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a broad spectrum of patients with diseases associated with impaired signaling of the transforming growth factor beta (“TGF-ß”) protein family, today announced that the Company has completed screening for the TROPOS study, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension (“PAH”). As a result, Keros expects to complete enrollment by the end of September and present topline data in the second quarter of 2025.

“We are very pleased to announce the completion of screening in the TROPOS study,” said Jasbir S. Seehra, Ph.D., Chairman and CEO. “The tremendous demand and the speed we have seen in enrolling participants in this study will enable us to present topline data sooner than expected, anticipated in the second quarter of 2025.”